• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真性红细胞增多症后骨髓纤维化:116例患者中该并发症的发生率及危险因素

Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.

作者信息

Alvarez-Larrán Alberto, Bellosillo Beatriz, Martínez-Avilés Luz, Saumell Silvia, Salar Antonio, Abella Eugenia, Gimeno Eva, Serrano Sergi, Florensa Lourdes, Sánchez Blanca, Pedro Carmen, Besses Carles

机构信息

Haematology Department, Hospital del Mar, IMIM, Barcelona, Spain.

出版信息

Br J Haematol. 2009 Sep;146(5):504-9. doi: 10.1111/j.1365-2141.2009.07804.x. Epub 2009 Jul 8.

DOI:10.1111/j.1365-2141.2009.07804.x
PMID:19604233
Abstract

Postpolycythaemic myelofibrosis (PPMF) is a known complication of polycythaemia vera (PV) but information regarding its incidence and predisposing factors is not well defined. In 116 subjects consecutively diagnosed with PV in a single institution (median age 62 years, range: 20-88), the probability of PPMF was analysed by the Kaplan-Meier method, followed by the log-rank test. With a mean follow-up of 8 years (95% confidence interval: 6.6-9), 17 patients had evolved into PPMF (15%). The probability of evolution to PPMF was 16% at 10 years and 34% at 15 years. Age, gender, spleen size, leucocytosis, thrombocytosis or cytoreductive treatment were not associated with an increased risk of PPMF. The actuarial probability of PPMF at 15 years was higher in those patients presenting at diagnosis with endogenous megakaryocytic colony formation (59% when present versus 10% when absent, P = 0.03), an elevated serum lactate dehydrogenase (LDH) level (69% vs. 23% in patients with normal LDH, P = 0.04), and in those who were heterozygous for the JAK2 V617F mutation (55% vs. 17% in heterozygotes, P = 0.04). In conclusion, PPMF is a frequent complication in PV patients at 15 years with the risk being higher in patients with increased LDH, endogenous megakaryocytic colony formation or a high JAK2 V617F allele burden.

摘要

真性红细胞增多症后骨髓纤维化(PPMF)是真性红细胞增多症(PV)的一种已知并发症,但关于其发病率和诱发因素的信息尚不明确。在一家机构连续诊断出的116例PV患者(中位年龄62岁,范围:20 - 88岁)中,采用Kaplan-Meier方法分析PPMF的发生概率,随后进行对数秩检验。平均随访8年(95%置信区间:6.6 - 9),17例患者发展为PPMF(15%)。10年时发展为PPMF的概率为16%,15年时为34%。年龄、性别、脾脏大小、白细胞增多、血小板增多或细胞减灭治疗与PPMF风险增加无关。诊断时出现内源性巨核细胞集落形成的患者15年时PPMF的精算概率更高(存在时为59%,不存在时为10%,P = 0.03),血清乳酸脱氢酶(LDH)水平升高的患者(LDH正常的患者为69%对23%,P = 0.04),以及JAK2 V617F突变杂合子患者(杂合子中为55%对17%,P = 0.04)。总之,PPMF是PV患者15年时常见的并发症,LDH升高、内源性巨核细胞集落形成或JAK2 V617F等位基因负荷高的患者风险更高。

相似文献

1
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.真性红细胞增多症后骨髓纤维化:116例患者中该并发症的发生率及危险因素
Br J Haematol. 2009 Sep;146(5):504-9. doi: 10.1111/j.1365-2141.2009.07804.x. Epub 2009 Jul 8.
2
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化中JAK2 V617F等位基因负荷——对疾病表型的影响
Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23.
3
A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.真性红细胞增多症中的一个der(18)t(9;18)(p13;p11)和一个der(9;18)(p10;q10),在向真性红细胞增多症后骨髓纤维化转化时伴有增殖性表型。
Cancer Genet Cytogenet. 2007 Jan 15;172(2):107-12. doi: 10.1016/j.cancergencyto.2006.09.015.
4
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.基于JAK2(V617F)等位基因负荷对高危真性红细胞增多症患者进行前瞻性识别。
Leukemia. 2007 Sep;21(9):1952-9. doi: 10.1038/sj.leu.2404854. Epub 2007 Jul 12.
5
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.JAK2 V617F时代真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的诊断与管理
Clin Adv Hematol Oncol. 2009 May;7(5):334-42.
6
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.年轻患者真性红细胞增多症:关于血栓形成、骨髓纤维化和白血病长期风险的研究
Haematologica. 2003 Jan;88(1):13-8.
7
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.真性红细胞增多症患者复杂核型伴新型 SETD1B/GTF2H3 融合基因。
Am J Hematol. 2014 Apr;89(4):438-42. doi: 10.1002/ajh.23659.
8
Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis.真性红细胞增多症后骨髓纤维化伴JAK2 V617F突变患者脾区放疗后发生肿瘤溶解综合征
Clin Oncol (R Coll Radiol). 2010 Dec;22(10):893. doi: 10.1016/j.clon.2010.07.002. Epub 2010 Aug 7.
9
[The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].[真性红细胞增多症患者发生血栓形成、骨髓纤维化及白血病转化的危险因素]
Zhonghua Xue Ye Xue Za Zhi. 2007 Oct;28(10):685-8.
10
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.年轻个体中的原发性血小板增多症:126例患者血管事件及向骨髓纤维化演变的发生率和危险因素
Leukemia. 2007 Jun;21(6):1218-23. doi: 10.1038/sj.leu.2404693. Epub 2007 Apr 12.

引用本文的文献

1
TLR2 Derangements Likely Play a Significant Role in the Inflammatory Response and Thrombosis in Patients with (-) Classical Myeloproliferative Neoplasm.TLR2 失调可能在 (-) 经典骨髓增殖性肿瘤患者的炎症反应和血栓形成中起重要作用。
Mediators Inflamm. 2024 Aug 9;2024:1827127. doi: 10.1155/2024/1827127. eCollection 2024.
2
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.迈向个体化定义费城阴性骨髓增殖性肿瘤的预后。
Curr Hematol Malig Rep. 2022 Oct;17(5):127-139. doi: 10.1007/s11899-022-00672-6. Epub 2022 Sep 1.
3
Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
JAK2(V617F)骨髓增殖性肿瘤患者中 PD-L1 的异位表达是通过 STAT3 和 STAT5 的激活增加介导的。
Hum Cell. 2020 Oct;33(4):1099-1111. doi: 10.1007/s13577-020-00370-6. Epub 2020 Jul 14.
4
Optimized and Personalized Phlebotomy Schedules for Patients Suffering From Polycythemia Vera.真性红细胞增多症患者的优化及个性化静脉采血计划
Front Physiol. 2020 Apr 17;11:328. doi: 10.3389/fphys.2020.00328. eCollection 2020.
5
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.真性红细胞增多症中持续性白细胞增多与疾病演变相关,但与血栓无关。
Blood. 2020 May 7;135(19):1696-1703. doi: 10.1182/blood.2019003347.
6
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.miR-146a rs2431697 可识别出骨髓增殖性肿瘤患者中具有较高继发性骨髓纤维化进展风险者。
Leukemia. 2020 Oct;34(10):2648-2659. doi: 10.1038/s41375-020-0767-3. Epub 2020 Feb 27.
7
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.原发性骨髓纤维化后 ET 和后 PV 骨髓纤维化:与原发性骨髓纤维化相比预后的新进展。
Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y.
8
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.原发性血小板增多症后和真性红细胞增多症后的患者与原发性骨髓纤维化患者有所不同。
Leuk Res. 2017 Aug;59:110-116. doi: 10.1016/j.leukres.2017.06.001. Epub 2017 Jun 2.
9
Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report.真性红细胞增多症后出现多器官受累的 Erdheim-Chester 病:一例报告
Medicine (Baltimore). 2016 May;95(20):e3697. doi: 10.1097/MD.0000000000003697.
10
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?真性红细胞增多症患者在使用羟基脲后进行二线细胞减灭治疗该何去何从?
Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14.